How large is the anakinra market, and what is its growth trajectory?
The anakinra market size has grown rapidly in recent years. It will grow from $4.89 billion in 2024 to $5.51 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to the increasing prevalence of rheumatoid arthritis, the approval of anakinra for treating rare autoinflammatory conditions like NOMID, rising awareness of biologics for managing chronic inflammatory conditions, and growing adoption of targeted therapies.
The anakinra market size is expected to see rapid growth in the next few years. It will grow to $8.81 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to the expansion of indications for anakinra in conditions, increasing focus on personalized medicine, rising prevalence of rare autoinflammatory disorders, advancements in drug delivery systems, and growing healthcare access in emerging markets driving demand for biologics. Major trends in the forecast period include the development of biosimilars and next-generation IL-1 inhibitors, the adoption of home-based and self-administered treatment options, collaborations between biotech companies and academic institutions, and digital health solutions to support patient adherence.
Get Your Free Sample of The Global Anakinra Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp
What are the key forces behind the anakinra market’s growth in recent years?
The rising incidence of autoimmune disorders is expected to propel the growth of the anakinra market going forward. Autoimmune disorders refer to problems that occur when the body’s immune system incorrectly assaults and destroys its own healthy tissues and organs, viewing them as foreign invaders. The rising incidence of autoimmune disorders is driven by genetic predisposition and environmental factors, such as infections, pollution, and dietary changes, all contributing to the growing occurrence of these disorders. Anakinra is used to treat autoimmune disorders by blocking interleukin-1 (IL-1) activity, reducing inflammation in conditions like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based governmental organization, in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year’s 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, the rising incidence of autoimmune disorders is driving the growth of the anakinra market.
Impact Of Rising Healthcare Expenditure On Market Growth
Rising healthcare expenditure is expected to propel the growth of the anakinra market going forward. Healthcare expenditure refers to the total amount of money spent on Healthcare and products, including hospital care, physician services, medications, medical devices, and public health initiatives. Healthcare expenditure is rising due to factors such as an aging population, medical advancements, chronic disease prevalence, higher drug prices, increased healthcare utilization, administrative costs, and inflation. Healthcare expenditure supports anakinra by funding the development, accessibility, and ongoing administration of this targeted biologic therapy, ensuring that it remains an effective treatment for inflammatory conditions like rheumatoid arthritis, while facilitating its integration into healthcare systems through insurance coverage and patient access programs. For instance, in May 2023, according to the Office for National Statistics, a UK-based government department, in 2022, UK healthcare expenditure reached approximately $352 billion (£283 billion), marking a 0.7% increase in nominal terms compared to 2021. Therefore, rising healthcare expenditure is driving the growth of the anakinra market.
What are the major segments of the anakinra market?
The anakinra market covered in this report is segmented –
1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report
Which companies dominate the anakinra market?
Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.
What major trends will shape the anakinra market during the forecast period?
Major companies operating in Anakinra market are gaining regulatory approvals to expand indications for new therapeutic applications. Regulatory approvals refer to official authorizations from government agencies that allow a drug to be marketed and prescribed for specific medical conditions after evaluating its safety, efficacy, and quality. For instance, in November 2022, the Food and Drug Administration, a US-based government agency, granted Emergency Use Authorization (EUA) for Kineret (anakinra) to treat hospitalized adults with COVID-19-related pneumonia requiring supplemental oxygen, aiming to reduce the risk of severe respiratory failure. The authorization was based on the SAVE-MORE phase 3 study, which showed that early treatment with Kineret improved patient outcomes. Kineret works by blocking cytokines IL-1a and IL-1ß, which contribute to the hyperinflammatory response in severe COVID-19 cases. While it is not fully FDA-approved for this indication, it is authorized for temporary use during the public health emergency.
What are the key regional dynamics of the anakinra market, and which region leads in market share?
North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Anakinra Market Report 2025 Offer?
The anakinra market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
